Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

VXRT 11.07.2024

Full Press ReleaseSEC FilingsOur VXRT Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
  • 01.14.2025 - Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
  • 12.02.2024 - Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Recent Filings

  • 01.21.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - 8-K Current report
  • 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

Conference call to begin at4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif.,Nov. 07, 2024(GLOBE NEWSWIRE) --Vaxart, Inc.(NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter endedSeptember 30, 2024, after the market close onWednesday, November 13, 2024. TheVaxartsenior management team will host a conference call on the same day, beginning at4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast:Click hereDate:Wednesday, November 13, 2024–4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13749666

Investors may submit written questions in advance of the conference call toir@vaxart.com.

A replay of the webcast will be available on the Company’s website atwww.vaxart.comfollowing the conclusion of the event.

AboutVaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@vaxart.com(646) 871-8481

Primary Logo

Source: Vaxart, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com